Company Profile
Updated: 26-OCT-09Chiesi S.A.
Non-Quoted Public Company
Immeuble Le Doublon, 11 Ave. Dubonnet, Courbevoie, F-92400, France
()33 01 47 68 88 99, 33 01 43 34 02 79 fax, http://www.chiesi.fr
Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Manufacturing: Manufacture of pharmaceuticals specialising in products for the follwoing areas: nutrition, cardiovascular medicine, respiratory medicine, gastroenterology, rhumatology and psychiatry
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Phenomix Grants Chiesi Farmaceutici European Rights to Dutogliptin for Diabetes.
Business Wire; 12/2/2009; 1142 words; ...markets. The company's internally discovered lead...California. About the Chiesi Group The Chiesi Group...Founded in Parma in 1935, Chiesi today operates globally...Research and Development. Chiesi's technologies and products...
The beauty queen, the hedge fund and the insider trading ring.(Business Report)
The Star (South Africa); 11/24/2009; 2359 words; ...hedge funds, has denied wrongdoing. Chiesi's lawyer, Alan Kaufman, said his...for information. Tarantino-like Chiesi's comments on wiretaps read like dialogue...partner at New Castle, encouraged Chiesi's source building, according to wiretaps...
Reportlinker Adds Pulmonary Drug Delivery Technologies - A Global Market Perspective.
PR Newswire; 11/18/2009; 2277 words; ...Montreal Protocol 17 FDA Bans the Use of CFC's in Metered Dose Inhalers 18 7. CORPORATE...Releases Meter Dose Inhalers 19 Trinity Chiesi Pharmaceuticals Introduces Fostair 19 BattellePharma...Baxter Healthcare Corporation (USA) 24 Chiesi Farmaceutici SpA (Italy) 24 Consort Medical...
Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results.(Financial report)
Biotech Week; 11/18/2009; 1881 words; ...strategic transaction with Chiesi Farmaceutici SpA -- Closed...Completed transaction with Chiesi to acquire rights to Curosurf...for review the Company's filing for an extended...Curosurf product rights from Chiesi during the third quarter...Spectracef by the Company's sales force to ...
Publication No. WO/2009/135579 Published on Nov. 12, Assigned to Chiesi Farmaceutici for 8-hydroxy-5- [(1r)-1-hydroxy-2- [[(1r) -2-(4-methoxyphenyl) -1-methylethyl] Amino] Ethyl] -2(1h)-Quinolinone Monohydrochloride Polymorph (Italian Inventors)
US Fed News Service, Including US State News; 11/13/2009; 408 words; ...1-methylethyl] amino] ethyl] -2(1h)-quinolinone monohydrochloride. The patent has been assigned to Chiesi Farmaceutici S.p.a., Parma, Italy. According to an abstract posted by the World Intellectual Property Organization...
Recent News Articles
- Phenomix Grants Chiesi Farmaceutici European Rights to Dutogliptin for Diabetes.
Business Wire - December 02, 2009 - Cornerstone Therapeutics Announces Closing of Chiesi Transaction.
Biotech Week - August 12, 2009 - Cornerstone Therapeutics Announces Closing of Chiesi Transaction.
PR Newswire - July 30, 2009 - El fabricante de Norlevo financia a un alto cargo de sanidad: la píldora del día después, un negocio familiar.(Chiesi Farmaceutici S.p.A.)
Epoca - June 26, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning